The Urologic clinics of North America | 2019

Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor.

 
 

Abstract


The introduction of cisplatin-based chemotherapy has revolutionized the care of patients with disseminated testicular germ cell tumors. Although a majority are cured with chemotherapy alone, surgical resection continues to play a role because one-third will have residual mass after chemotherapy. In this article, we review the current indications for postchemotherapy resection in nonseminomatous germ cell tumors, including masses greater than 1\xa0cm, resection after salvage chemotherapy, with elevated markers, after late relapse, and for growing teratoma syndrome. We also highlight technical considerations of this often-challenging surgery, including the need for adjunctive procedures, extraretroperitoneal resections, and modern techniques to minimize morbidity.

Volume 46 3
Pages \n 389-398\n
DOI 10.1016/J.UCL.2019.04.004
Language English
Journal The Urologic clinics of North America

Full Text